Hipofosfatemia asociada a la administración intravenosa de hierro carboximaltosa en pacientes con anemia ferropénica. Un efecto secundario frecuente
- 1 August 2015
- journal article
- research article
- Published by Elsevier in Medicina Clinica
- Vol. 145 (3) , 108-111
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Hipofosfatemia, una reacción adversa poco conocida del hierro intravenosoMedicina Clinica, 2014
- Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective studyBMC Nephrology, 2013
- Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in womenJournal of Bone and Mineral Research, 2013
- Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency AnemiaAnemia, 2013
- Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled TrialsAnemia, 2012
- Ferric Carboxymaltose in Patients with Heart Failure and Iron DeficiencyNew England Journal of Medicine, 2009
- FGF23 Elevation and Hypophosphatemia after Intravenous Iron Polymaltose: A Prospective StudyThe Journal of Clinical Endocrinology & Metabolism, 2009
- Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalaciaAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2009
- Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trialAmerican Journal of Obstetrics and Gynecology, 2008